	Application No.	Applicant(s)
Nation of Allamability	10/776,889	KINNEY ET AL.
Notice of Allowability	Examiner	Art Unit
	Vinod Kumar	1638
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to papers filed May 4, 2006 and interview of June 6, 2006.		
2. The allowed claim(s) is/are <u>2 and 5-13</u> .		
 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. ☐ Notice of Informal P	atent Application (PTO-152)
Notice of Draftperson's Patent Drawing Review (PTO-948)	6. 🛛 Interview Summary	(PTO-413),
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0	Paper No./Mail Dat 08), 7. ⊠ Examiner's Amendr	
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit	_	ent of Reasons for Allowance
of Biological Material	9.	

Page 2

Application/Control Number: 10/776,889

Art Unit: 1638

DETAILED ACTION

Status of Objections and Rejections

- 1. The objection to specification is withdrawn in light of abstract amendment.
- 2. The objection to claims 5-13 is withdrawn in light of claim amendment.
- 3. The rejections to claims 1, 5-13 under 35 U.S.C. 112, first paragraph, are withdrawn in light of Examiner's amendment.

EXAMINER'S AMENDMENT

4. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Lynne Christenbury (Reg. No. 30,971) on June 6, 2006.

In the claims:

Claim 1 has been cancelled.

Claim 5. (amended) A recombinant expression construct comprising at least one heterologous nucleic acid fragment operably linked to any one of the isolated nucleic acid fragments of [any of] claim[s 1 or] 2.

Application/Control Number: 10/776,889

Art Unit: 1638

38

Claim 13. (amended) A method for regulating expression of at least one heterologous nucleotide sequence in the seeds of a plant which comprises: (a) transforming a plant cell with a recombinant expression construct comprising at least one heterologous nucleic acid fragment operably linked to the isolated nucleic acid fragment of [any of] claim[s 1 or] 2; (b) growing fertile mature plants from transformed plant cell of step (a); and (c) selecting plants comprising the recombinant expression construct wherein the heterologous nucleotide sequence is expressed in the seeds of the transformed plant during early seed development.

Conclusions

5. Claims 2 and 5-13 are allowed.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vinod Kumar whose telephone number is (571) 272-4445. The examiner can normally be reached on 8.30 a.m. to 5.00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on (571) 272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ASHWIN D. MEHTA, PH.D. PRIMARY EXAMINER

Page 3